The safety and efficacy of Laparoscopic Gastric Plication versus Laparoscopic sleeve gastrectomy in the treatment of morbid obesity

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2013123012294N5

Enrollment

Registered

2015-06-01

Start date

2012-04-08

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Morbid obesity. Morbid obesity

Interventions

Intervention 1: Laparoscopic Gastric Plication. Intervention 2: Laparoscopic Sleeve Gasterectomy.

Treatment - Surgery

Laparoscopic Gastric Plication

Laparoscopic Sleeve Gasterectomy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: morbid obesity ( BMI>40 kg/m2 or BMI>35kg/m2 with co-existing morbidities ); age 18 to 65; previous unsuccessful weight loss attempts Exclusion criteria: previous restrictive or malabsorptive procedure for obesity treatment; previous gastric surgery; history of anti-reflux surgery; pregnancy

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Percent of excess weight loss. Timepoint: 24 months after surgery. Method of measurement: Weighing.;Operative time. Timepoint: During surgery. Method of measurement: With a clock.;Length of hospitalization. Timepoint: after discharging. Method of measurement: days of hospitalization.;Hypertension. Timepoint: 24 months follow-up. Method of measurement: clinical examination and non invasive blood pressure measurement.;Diabetes. Timepoint: 24-months follow-up. Method of measurement: FBS , HgA1c.;Hyperlipidemia. Timepoint: 24 months follow-up. Method of measurement: cholesterol level,triglyceride.	—

Measure

Time frame

Percent of excess weight loss. Timepoint: 24 months after surgery. Method of measurement: Weighing.;Operative time. Timepoint: During surgery. Method of measurement: With a clock.;Length of hospitalization. Timepoint: after discharging. Method of measurement: days of hospitalization.;Hypertension. Timepoint: 24 months follow-up. Method of measurement: clinical examination and non invasive blood pressure measurement.;Diabetes. Timepoint: 24-months follow-up. Method of measurement: FBS , HgA1c.;Hyperlipidemia. Timepoint: 24 months follow-up. Method of measurement: cholesterol level,triglyceride.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactReza Heidari

School of Medicine, Tehran University of Medical Science

heidari.reza1@yahoo.com+98 938 393 8459

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Mar 7, 2026